ICER stands by view on Biogen’s Aduhelm, says sharp price cut needed

The influential nonprofit maintains that the clinical trial evidence supporting Aduhelm is insufficient to prove a health benefit. But even if some efficacy is assumed, ICER argues Biogen’s $56,000 price tag is far too high.